tiprankstipranks
Trending News
More News >
Hannover Rueck SE (HVRRY)
OTHER OTC:HVRRY

Hannover Rueck SE (HVRRY) AI Stock Analysis

Compare
25 Followers

Top Page

HVRRY

Hannover Rueck SE

(OTC:HVRRY)

Select Model
Select Model
Select Model
Outperform 76 (OpenAI - 4o)
Rating:76Outperform
Price Target:
$57.00
▲(11.96% Upside)
Hannover Rueck SE's strong financial performance and positive earnings call are the most significant factors contributing to its score. The company shows robust revenue growth and profitability, with effective equity utilization. The technical analysis indicates a neutral trend, while the valuation is reasonable with an attractive dividend yield. The earnings call highlights substantial growth and increased guidance, reinforcing the company's strong position in the industry.
Positive Factors
Revenue Growth
The significant growth in the Life & Health segment indicates strong demand and effective market penetration, supporting long-term revenue expansion.
Strong Solvency and Capitalization
A robust solvency ratio ensures financial stability and the ability to withstand adverse conditions, supporting sustainable growth.
Increased Guidance
Raising guidance reflects management's confidence in continued strong performance and enhances investor trust in the company's future prospects.
Negative Factors
Declining Free Cash Flow
A decline in free cash flow may limit the company's ability to invest in growth opportunities and maintain financial flexibility.
Currency Translation Impact
Currency translation impacts can affect financial stability and reported earnings, potentially leading to volatility in financial performance.
Fixed Income Losses
Realizing fixed income losses may impact short-term earnings and reflects challenges in managing investment portfolios amid changing market conditions.

Hannover Rueck SE (HVRRY) vs. SPDR S&P 500 ETF (SPY)

Hannover Rueck SE Business Overview & Revenue Model

Company DescriptionHannover Rück SE, together with its subsidiaries, provides reinsurance products and services worldwide. It operates through Property & Casualty Reinsurance, and Life & Health Reinsurance segments. The company offers property, casualty, facultative, catastrophe XL, structured reinsurance, and insurance-linked securities. It also provides risk solutions for agricultural, livestock, and bloodstock businesses; aviation and space business; and marine and offshore energy business, as well as credit, surety, and political risks reinsurance products. In addition, the company offers group and individual credit life, enhanced annuities, group life and health, and Takaful reinsurance products; and risk solutions in the areas of critical illness, disability, health, longevity, long term care, mortality, and morbidity. Further, it provides various financial solutions, including new-business financing; monetization of embedded value; reserve and solvency relief; and divestiture of non-core businesses. The company was formerly known as Hannover Rückversicherung AG and changed its name to Hannover Rück SE in March 2013. The company was founded in 1966 and is headquartered in Hanover, Germany. Hannover Rück SE is a subsidiary of Talanx AG.
How the Company Makes MoneyHannover Re generates revenue primarily through its reinsurance operations. The company earns money by underwriting reinsurance contracts, where it assumes part of the risk from primary insurers in exchange for premium payments. Key revenue streams include property and casualty reinsurance, life and health reinsurance, and specialty reinsurance products. Additionally, Hannover Re invests premiums in various asset classes, generating investment income. The company's strong relationships with insurance clients and its global presence, along with its expertise in risk assessment and management, contribute to its earnings. Significant partnerships with insurers and strategic collaborations in various regions also enhance its market position and revenue potential.

Hannover Rueck SE Earnings Call Summary

Earnings Call Date:Nov 10, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Mar 12, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong overall performance with substantial growth in net income and increased guidance. While there are strategic realizations of fixed income losses and currency impact challenges, the positive developments in P&C and Life & Health segments, along with a robust investment strategy, signify a strong position for future growth.
Q3-2025 Updates
Positive Updates
Strong Net Income and Increased Guidance
The group net income reached EUR 1.96 billion for the first 9 months, leading to an increase in the full-year guidance to EUR 2.6 billion. This performance reflects strong profitability and favorable currency and tax effects.
P&C Reinsurance Growth
The adjusted growth rate for the P&C reinsurance portfolio was close to 10%, surpassing the 7% growth target, in a favorable rate environment.
Life & Health Reinsurance Performance
Revenue in the Life & Health reinsurance segment grew by 16% in new business generation, with a positive reinsurance service result of EUR 671 million.
Robust Investment Strategy
The company realized EUR 324 million in fixed income losses to improve future investment returns, with a planned ROI of 2.9% for the full year.
Strong Solvency and Capitalization
The solvency ratio remained strong at 259%, with successful capital deployment and a positive impact from planned growth for 2026.
Negative Updates
Currency Translation Impact
Negative currency translation effects impacted the shareholders’ equity and OCI, partially offsetting other gains.
Realization of Fixed Income Losses
The company realized over EUR 300 million in losses in the fixed income portfolio, reflecting deliberate strategy adjustments.
Run-off Result in P&C Reinsurance
The P&C run-off result was negative EUR 465 million, influenced by prudent reserving and updates related to Russia-Ukraine aviation losses.
Challenges in Greater China
The Life & Health reinsurance segment faced challenges in Greater China, leading to cautious positioning and increased risk adjustment for the morbidity business.
Company Guidance
During the earnings call, Hannover Re provided guidance for the financial year 2026, setting a group net income target of at least EUR 2.7 billion, marking a 12.5% increase from the initial guidance for 2025. The company aims for a combined ratio target below 87% for its P&C business, despite anticipated softening rates, and expects a return on investment of around 3.5%. Key metrics include a solvency ratio of 259%, a reinsurance service result target of EUR 925 million for Life & Health, and a projected return on equity of 22%. The company also anticipates mid-single-digit growth in its P&C business, excluding structured reinsurance, and a CSM growth target of around 2%. Additionally, Hannover Re plans to leverage market conditions to improve investment returns by realizing fixed income losses, with a focus on locking in higher interest rates to support future earnings growth.

Hannover Rueck SE Financial Statement Overview

Summary
Hannover Rueck SE demonstrates strong financial health with robust revenue growth and profitability. The balance sheet is stable with manageable leverage, and the company effectively utilizes its equity. However, declining free cash flow growth and increasing debt levels warrant attention to ensure continued financial stability.
Income Statement
85
Very Positive
Hannover Rueck SE shows strong revenue growth with a 12.41% increase in TTM, indicating robust business expansion. The company maintains healthy profitability with a gross profit margin of 92.80% and a net profit margin of 8.78%. EBIT and EBITDA margins are stable at 11.81%, reflecting efficient operational management. However, the slight decline in net profit margin from the previous year suggests potential cost pressures.
Balance Sheet
78
Positive
The balance sheet is solid with a manageable debt-to-equity ratio of 0.37, indicating prudent leverage. Return on equity is impressive at 21.53%, showcasing effective use of equity capital. The equity ratio stands at 15.99%, suggesting a stable capital structure. However, the slight increase in debt levels over the past year could pose a risk if not managed carefully.
Cash Flow
70
Positive
Operating cash flow remains strong, but free cash flow has declined by 7.60% in the TTM, which may impact future investment capabilities. The free cash flow to net income ratio of 0.78 indicates that a significant portion of earnings is being converted into cash, although this is lower than the previous year. The company needs to monitor cash flow closely to maintain financial flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.15B2.66B1.13B1.39B26.15B23.28B
Gross Profit1.15B2.53B1.04B1.31B20.39B18.24B
EBITDA3.47B3.37B2.01B1.44B1.85B1.39B
Net Income2.48B2.33B1.82B780.80M1.23B883.07M
Balance Sheet
Total Assets69.36B72.13B65.67B86.95B82.90B71.44B
Cash, Cash Equivalents and Short-Term Investments54.67B57.39B1.05B46.65B47.59B40.97B
Total Debt4.11B4.67B4.77B5.51B4.37B3.43B
Total Liabilities57.40B59.44B54.65B78.20B70.15B59.60B
Stockholders Equity11.10B11.79B10.13B9.06B11.89B11.00B
Cash Flow
Free Cash Flow5.26B5.68B5.79B5.16B4.60B2.86B
Operating Cash Flow5.26B5.68B5.79B5.16B4.94B3.23B
Investing Cash Flow-3.32B-4.41B-4.51B-5.38B-5.26B-2.24B
Financing Cash Flow-1.82B-1.10B-1.50B133.25M277.51M-726.04M

Hannover Rueck SE Technical Analysis

Technical Analysis Sentiment
Positive
Last Price50.91
Price Trends
50DMA
49.53
Positive
100DMA
49.52
Positive
200DMA
50.10
Positive
Market Momentum
MACD
0.21
Negative
RSI
61.10
Neutral
STOCH
91.19
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HVRRY, the sentiment is Positive. The current price of 50.91 is above the 20-day moving average (MA) of 49.50, above the 50-day MA of 49.53, and above the 200-day MA of 50.10, indicating a bullish trend. The MACD of 0.21 indicates Negative momentum. The RSI at 61.10 is Neutral, neither overbought nor oversold. The STOCH value of 91.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HVRRY.

Hannover Rueck SE Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$34.06B8.7917.81%16.68%-28.54%
78
Outperform
$12.56B7.5714.98%0.59%-3.96%-48.08%
76
Outperform
$34.39B12.6622.23%3.68%4.35%12.64%
74
Outperform
$13.34B15.687.19%1.79%2.10%19.23%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
64
Neutral
$13.73B24.283.59%2.45%8.62%-78.92%
60
Neutral
$45.81B15.227.68%2.00%-23.02%52.43%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HVRRY
Hannover Rueck SE
50.91
7.49
17.25%
AIG
American International Group
84.90
13.95
19.66%
ACGL
Arch Capital Group
93.92
2.58
2.82%
EG
Everest Group
327.16
-22.26
-6.37%
RGA
Reinsurance Group
203.37
-4.17
-2.01%
RNR
Renaissancere Holdings
272.41
13.45
5.19%

Hannover Rueck SE Corporate Events

Hannover Rueck SE Reports Strong Q3 2025 Earnings
Nov 11, 2025

Hannover Rueck SE (ADR) is a leading global reinsurance company, operating primarily in the property and casualty, as well as life and health reinsurance sectors, known for its robust risk management and strategic growth initiatives.

Hannover Rueck SE Reports Strong H1 2025 Performance
Aug 13, 2025

Hannover Rueck SE (ADR) is a leading global reinsurance company, specializing in property and casualty as well as life and health reinsurance, known for its robust business model and adaptability to changing risk landscapes. In its latest earnings report for the first half of 2025, Hannover Re reported a solid performance with a 3.3% increase in reinsurance revenue, reaching EUR 13.3 billion, and a significant 13.2% rise in group net income to EUR 1.3 billion. The company also achieved a return on equity of 23.0%, reflecting strong profitability despite slightly higher-than-expected large loss expenditures. Key financial metrics highlighted include a 6.3% improvement in operating profit (EBIT) to EUR 1.76 billion and a 3.6% increase in investment results to EUR 1.05 billion. The company’s solvency ratio remains robust at 261%, comfortably above its target, ensuring financial stability. Looking ahead, Hannover Re remains focused on profitable growth and maintaining its position as a reliable partner in the reinsurance industry, with management expressing confidence in achieving full-year targets despite ongoing geopolitical and economic challenges.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 12, 2025